Evaluation of an integrated orbital tissue expander in congenital anophthalmos: report of preliminary clinical experience.
Evaluation of an integrated orbital tissue expander in congenital anophthalmos: report of preliminary clinical experience.
复制标题
先天性无眼症综合眼眶组织扩张器的评估：初步临床经验报告。
DOI：
10.1016/j.ajo.2010.09.009
复制
发表时间：
2011
影响因子：
4.2
通讯作者：
Pinchuk,Leonard
中科院分区：
文献类型：
--
作者：
Tse,DavidT;Abdulhafez,Mohammad;Orozco,MarciaA;Tse,JeffreyD;Azab,AmrOsama;Pinchuk,Leonard
目的：评价眼眶组织扩张器的有效性，旨在刺激眼眶骨生长在一个无眼插座。研究人群：9例单侧先天性无眼的连续患者。干预措施：眼眶组织扩张器由可膨胀的硅胶地球仪制成，在钛T型板上滑动，钛T型板用螺钉固定在外侧眼眶边缘。通过30号针头经结膜注射生理盐水使地球仪膨胀至最终体积约为5 cm 3。计算机断层扫描用于确定眼眶体积。研究的数据包括：人口统计学、既往眼眶扩张术、二次介入、眼眶对称性和植入物相关并发症。主要结局指标：主要结果指标为眼眶体积变化，次要结果指标为前额、眉毛和颧骨隆起轮廓的变化以及不良事件。植入时患者平均年龄为41.89 ± 39.42个月（范围，9至108个月）。初始平均充盈体积为3.00 ± 0.87 cm 3（范围：2.0 - 4.0 cm 3），最终平均充盈体积为4.33 ± 0.50 cm 3（范围：4.0 - 5.0 cm 3）。扩张持续时间为18.89 ± 8.80个月（范围4 ~ 26个月）。所有患者的眼眶组织扩张器植入后，眼眶体积平均增加5.112 ± 2.173 cm 3（范围：2.81 - 10.38 cm 3）。植入眼眶与初始对侧眼眶体积之间的平均差异为5.68 ± 2.34 cm 3，最终测量时降至2.53 ± 1.80 cm 3（P <0.001，配对t检验）。除第二次充盈时发生2例医源性穿刺和1例植入物失效外，所有植入物均保持充盈状态。结论：一体化眼眶组织扩张器在促进无眼窝骨生长方面是安全有效的。
PURPOSETo evaluate the effectiveness of an orbital tissue expander designed to stimulate orbital bone growth in an anophthalmic socket.DESIGNRetrospective, noncomparative, interventional case series.METHODSsettings: Institutional. Study Population: Nine consecutive patients with unilateral congenital anophthalmos. Intervention: The orbital tissue expander is made of an inflatable silicone globe sliding on a titanium T-plate secured to the lateral orbital rim with screws. The globe is inflated by a transconjunctival injection of normal saline through a 30-gauge needle to a final volume of approximately 5 cm3. Computed tomography scans were used to determine the orbital volume. The data studied were: demographics, prior orbital expansion procedures, secondary interventions, orbital symmetry, and implant-related complications. Main Outcome Measures: The primary outcome measure was the orbital volume change, and the secondary outcome measures were changes in forehead, brow, and zygomatic eminence contour and adverse events.RESULTSThe average patient age at implantation was 41.89 ± 39.42 months (range, 9 to 108 months). The initial average volume of inflation was 3.00 ± 0.87 cm3(range, 2.0 to 4.0 cm3), and the average final volume of 4.33 ± 0.50 cm3(range, 4.0 to 5.0 cm3) was achieved. The duration of expansion was 18.89 ± 8.80 months (range, 4 to 26 months). All patients demonstrated an average increase in the orbital tissue expander implanted orbital volume of 5.112 ± 2.173 cm3(range, 2.81 to 10.38 cm3). The average difference between the volume of the implanted and the initial contralateral orbit was 5.68 ± 2.34 cm3, which decreased to 2.53 ± 1.80 cm3at the final measurement (P < .001, paired t test). All implants remained inflated except for 2 iatrogenic punctures at the second inflation and 1 that was the result of implant failure. All were replaced.CONCLUSIONSThe integrated orbital tissue expander is safe and effective in stimulating anophthalmic socket bone growth.